TSTickerStarGet alerts

DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform and Other Assets from Estate of Todos Medical

DataMeds AI, Inc. (NASDAQ: MEDS) announced it has agreed to acquire certain assets from the estate of Todos Medical Ltd., including its Cancer AI Total Biochemical Infrared Analysis (TBIA) blood tests for breast cancer (TM-B1 and TM-B2) and colorectal cancer (TM-C1), originally developed at Ben Gurion University in Israel. Other assets include Todos' license to the LymPro Alzheimer's diagnostic blood test and 100% of the shares of Todos Medical Singapore PTE Ltd., which held equity in Pathnova Labs PTE Ltd. that...

Share this story

Key takeaways

  • DataMEDS AI agreed to acquire certain assets from the estate of Todos Medical Ltd., including the TBIA Cancer AI blood tests for breast cancer (TM-B1 and TM-B2) and colorectal cancer (TM-C1), originally developed at Ben Gurion University (BGU) in Israel.

  • TBIA platform uses Fourier-transform infrared (FTIR) spectroscopy of blood plasma and PBMC components to distinguish healthy subjects from cancer patients, and is designed to multiplex algorithms for multiple cancer tests from a single blood draw.

  • Additional assets include Todos' license to the LymPro Alzheimer's diagnostic blood test and 100% of the shares of Todos Medical Singapore PTE Ltd., which previously owned equity in Pathnova Labs PTE Ltd. that was exchanged for Archerfish Precision Diagnostics Pte Ltd. shares following Pathnova's merger with Angsana Molecular & Diagnostics Laboratory.

  • The agreement is subject to court approval; no purchase price, consideration structure, or closing timeline was disclosed.

  • The spectroscopy platform is to be transferred to Helomics (Pittsburgh, PA) to revalidate data correlations with biopsies and imaging and to support an LDT launch prior to FDA submissions.

  • Issued U.S. and European patents provide market exclusivity into at least 2034; CE marks were previously held in Europe for the breast cancer and colorectal cancer tests.

  • The TBIA tests have not been cleared or approved by the FDA and are not currently commercially available in the United States.

Key metrics

Global cancer diagnostics market size2024
USD 189.19 billion
Global cancer diagnostics market size (projected)2035
USD 386.19 billion
Patent exclusivity period for TBIA platform
into at least 2034
ChemoFx Assay CPT billing codes
81535 and 81536
Helomics Predictive Oncology annotated biobank tumor types
over 130 tumor types

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open Investor relations

Follow MEDS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert